At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,374 enrolled
Drug / intervention
Alogliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Nesina Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"
In Brief
An observational study evaluating Alogliptin for Type 2 Diabetes Melitus. Completed, enrolled 1,374 participants.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of long-term combination therapy with alogliptin (Nesina) and thiazolidinediones in patients with type 2 diabetes mellitus who failed to respond adequately to treatment with thiazolidinediones in addition to diet therapy and exercise therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Melitus
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedSep 2013
Primary CompletionJun 2014
TodayJul 2026
First PostedSep 18, 2013
Enrollment StartMar 1, 2011
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.8 years ago
Interventions
Alogliptindrug
Alogliptin tablets